Arturo Garcia
Medical · El Centro, CANPI 1316323736
Payments from drug & device makers
Across 142 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$994
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$297
- Amgen$271
- Lilly USA, LLC$253
- Boston Scientific$193
- Redhill Biopharma Inc.$130
- plus $413 from 10 others
What the payments were for
- Food & beverage$2,551100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $994 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $297 |
| Amgen(2 entities) | 13 | $271 |
| Lilly USA, LLC | 12 | $253 |
| Boston Scientific | 14 | $193 |
| Redhill Biopharma Inc. | 12 | $130 |
| Electronic Waveform Lab, Inc. | 4 | $104 |
| AbbVie | 3 | $81 |
| AstraZeneca | 3 | $58 |
| Corcept Therapeutics | 1 | $56 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Bayer | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,551 in reported general payments places this provider in the 75th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $101,840 |
| RybelsusSemaglutide | 53 | $70,982 |
| JardianceEmpagliflozin | 18 | $19,435 |
| FarxigaDapagliflozin Propanediol | 23 | $18,441 |
| Repatha SureclickEvolocumab | 18 | $11,441 |
| TrulicityDulaglutide | 12 | $10,716 |
| Bydureon BciseExenatide Microspheres | 12 | $9,123 |
| VascepaIcosapent Ethyl | 25 | $8,243 |
| Icosapent Ethyl | 34 | $8,037 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $6,636 |
| Rosuvastatin Calcium | 232 | $4,432 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $1,882 |
| Metformin Hcl | 225 | $1,538 |
| Atorvastatin Calcium | 112 | $1,329 |
| Lisinopril | 152 | $1,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $994 | $172,822171 claims |
| AstraZenecaFarxiga | $58 | $18,44123 claims |
| Lilly USA, LLCTrulicity | $253 | $10,71612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 medical providers in California.
Other medical in El Centro
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.